Benign prostatic hyperplasia ( BPH ) is the most common benign disease in middle-aged and elderly men over 50 years old in the world. With the aggravation of population aging, the incidence of prostate disease is increasing year by year. Studies have found that there are many kinds of inflammasomes in prostate tissue, which are involved in various inflammatory reactions and play an important role in prostate diseases. As a key regulatory factor of inflammatory response, inflammasome has attracted more and more attention in the research field of benign prostatic hyperplasia. This article reviews the mechanism, research progress and potential treatment strategies of inflammasome in benign prostatic hyperplasia